Arcturus Therapeutics Holdings Inc. (ARCT) Operating Income (Loss) USD 2018 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Arcturus Therapeutics Holdings Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2018 to 2024.
  • Arcturus Therapeutics Holdings Inc. Operating Income (Loss) for the quarter ending March 31, 2024 was -$30.4 M, a 306% decline year-over-year.
  • Arcturus Therapeutics Holdings Inc. Operating Income (Loss) for the twelve months ending March 31, 2024 was -$123 M, a 260% decline year-over-year.
  • Arcturus Therapeutics Holdings Inc. annual Operating Income (Loss) for 2023 was -$78.2 M, a 742% decline from 2022.
  • Arcturus Therapeutics Holdings Inc. annual Operating Income (Loss) for 2022 was $12.2 M.
  • Arcturus Therapeutics Holdings Inc. annual Operating Income (Loss) for 2021 was -$203 M, a 184% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$123 M -$30.4 M -$45.2 M -306% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$78.2 M -$18.3 M -$140 M -115% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 $61.5 M -$19.3 M +$17.5 M +47.5% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $44 M -$55.4 M -$33.3 M -151% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-07
Q1 2023 $77.3 M $14.8 M +$65.1 M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $12.2 M $121 M +$159 M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 -$147 M -$36.8 M +$17 M +31.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$164 M -$22.1 M +$31.6 M +58.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 -$196 M -$50.4 M +$7.29 M +12.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$203 M -$37.6 M -$6.56 M -21.1% Oct 1, 2021 Dec 31, 2021 10-K 2022-03-01
Q3 2021 -$196 M -$53.8 M -$32.9 M -157% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$163 M -$53.7 M -$43.7 M -435% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$120 M -$57.7 M -$48.2 M -509% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 -$71.5 M -$31.1 M -$20.3 M -187% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-01
Q3 2020 -$51.3 M -$20.9 M -$13.3 M -175% Jul 1, 2020 Sep 30, 2020 10-K 2022-03-01
Q2 2020 -$37.9 M -$10 M -$9.47 M -1656% Apr 1, 2020 Jun 30, 2020 10-K 2022-03-01
Q1 2020 -$28.5 M -$9.46 M -$2.95 M -45.4% Jan 1, 2020 Mar 31, 2020 10-K 2022-03-01
Q4 2019 -$25.5 M -$10.8 M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 -$7.62 M -$3.26 M -74.8% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-01
Q2 2019 -$572 K +$9.5 M +94.3% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-01
Q1 2019 -$6.51 M Jan 1, 2019 Mar 31, 2019 10-K 2021-03-01
Q3 2018 -$4.36 M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 -$10.1 M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.